AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
ABBV- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the...
AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
ABBVNORTH CHICAGO, Ill., Jan. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time. A live audio webcast of the presentation will...
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
ABBV(NYSE:ABBV) Data presented at 13th Society of Hematologic Oncology (SOHO) Annual Meeting NORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring...
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
ABBV(NYSE:ABBV) First-of-its-kind report is available at www.naturallyyouwithHA.com Deep dive into category education and data on HA injectable fillers and the natural-looking results they can achieve IRVINE, Calif., Sept. 3, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, has launched the...
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
ABBV(NYSE:ABBV) NORTH CHICAGO, Ill., Sept. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025. Management will participate in a fireside chat at 9:00 a.m. Central time. A live audio webcast of the...
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
ABBVGilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser. NORTH...
AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
ABBVIn the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or...
AbbVie Completes Acquisition of Capstan Therapeutics
ABBVAcquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell...
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
ABBVNew $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S. Expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade...
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)
ABBVFDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.
How Is The Market Feeling About AbbVie?
ABBVFDA Approves Label Expansion For AbbVie's MAVYRET, Oral Pangenotypic Direct Acting Antiviral Therapy
ABBVAt Goldman Sachs Conference, AbbVie CEO Reportedly Says Conversations With President Donald Trump On Drug Pricing Reform Have Been Productive; On Drug Pricing Reform, Says Quite A Long Way To Go In Terms Of Reaching An Agreement
ABBVRecent Filing Shows That Rep. Robert Bresnahan Bought Over $28K Worth of AbbVie Stock
ABBVAnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
ABBVRosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
9 Health Care Stocks Whale Activity In Today's Session
ABBVMeta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades'
ABBVCNBC Halftime Report Final Trades: Meta Platforms, JP Morgan Chase & Co., The Gap, AbbVie
ABBVCNBC Halftime Report Final Trades: Meta Platforms, JP Morgan Chase & Co., Gap, AbbVie
ABBV10 Health Care Stocks Whale Activity In Today's Session
ABBVSarah Cannon Research Institute Announces Strategic Alliance With AbbVie To Advance Cancer Therapies
ABBV10 Health Care Stocks Whale Activity In Today's Session
ABBVAbbVie To Present Cancer Trial Data At Upcoming ASCO Event
ABBVAbbVie shares new data for Temab-A, ABBV-706, and PVEK across lung, colorectal, and blood cancers ahead of the ASCO oncology conference.
AbbVie Says Key Data From Broad Oncology Portfolio To Be Showcased Across Multiple Oral Presentations And Posters At 2025 ASCO Annual Meeting
ABBV10 Health Care Stocks With Whale Alerts In Today's Session
ABBV3 Stocks That Will Profit From Trump's Drug Price Cut
ABBVTrump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
ABBVFor investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets
ABBVRising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
ABBVFDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.
AbbVie Announces That EMRELIS Has Been Granted Accelerated Approval By The FDA For The Treatment Of Adult Patients With Locally Advanced Or Metastatic, Non-Squamous Non-Small Cell Lung Cancer With High C-Met Protein Overexpression Who Have Received A Pri
ABBVExpert Outlook: AbbVie Through The Eyes Of 10 Analysts
ABBVAbbVie And ADARx Pharma Announce Collaboration And License Option Agreement To Develop siRNA Therapeutics Across Multiple Disease Areas, Including Neuroscience, Immunology And Oncology
ABBVCitigroup Downgrades AbbVie to Neutral, Lowers Price Target to $205
ABBVA Look Into AbbVie Inc's Price Over Earnings
ABBVWhat Does the Market Think About AbbVie?
ABBVAbbVie Unusual Options Activity
ABBVCongressional Trading Report: Rep. Jared Moskowitz Bought Over $27K In AbbVie Stock
ABBVWall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
ABBVUS-China agree to slash tariffs by over 100%, easing fears of economic slowdown and inflation. Markets cheer with futures rising and yields up.
10 Health Care Stocks With Whale Alerts In Today's Session
ABBVTrump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns
ABBVPresident Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
ABBVFDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.
8 Health Care Stocks Whale Activity In Today's Session
ABBVNetflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades'
ABBVCNBC Halftime Report Final Trades: Netflix, AbbVie, iShares U.S. Industrials, Sherwin-Williams Company
ABBVHere's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
ABBVGuggenheim Maintains Buy on AbbVie, Raises Price Target to $216
ABBVAbbvie: FDA Approves RINVOQ, 15 Mg, Once Daily, For Treatment Of Adults With Giant Cell Arteritis
ABBVAbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
ABBVAnalysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.
AbbVie's Options Frenzy: What You Need to Know
ABBVEvercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $205
ABBV